Plain-English translation of NCT05962840 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing whether a medication called can help prevent relapses in people with ANCA-associated vasculitis (a disease where the immune system attacks blood vessels). You would receive as a weekly injection for one year, after your disease has been brought under control with other standard treatments. Half the participants will receive the real medication, and half will receive a placebo (inactive injection) to see which works better.
ANCA-associated vasculitis tends to keep coming back even after treatment, which can cause serious damage. This trial exists because researchers want to find better ways to keep the disease in remission and prevent these dangerous relapses. The medication being tested has shown promise in other autoimmune diseases, but has never been studied for vasculitis prevention.
You likely qualify if…
You likely don't qualify if…
You would first receive standard treatments (Rituximab and steroids) to bring your disease under control. Once your disease is in remission, you would receive a weekly injection of either the new medication or placebo for 12 months, with the steroid dose gradually reduced following current guidelines. You would have regular clinic visits to monitor how you're doing and check for any side effects or signs of relapse.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China